Unaudited Interim Results to 30 June 2026

About this update from Probiotix Health Plc

6 August 2026 ProBiotix Health plc ("ProBiotix" or the "Company") Unaudited Interim Results to 30 June 2026 ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2026. Key Financial Highlights ·    Gross revenue +53% to £2.06m (H1 2025: £1.34m) ·    Gross profit +66% to £1.245m (H1 2025: £748,000) ·    EBITDA profit £151,000* (H1 2025: £112,000 loss) ·    Strong cash balance of £1.244m (H1 2025: £1.3m) *Excluding share-based payments Operational Highlights ·    Five new partnerships established ·    Significant growth of existing customer base ·    Strong growth in China through Kemin partnership ·    Repositioned US strategy for stronger market penetration in 2027 ·    Recruitment for clinical study to investigate potential impact of LP LDL ® in prediabetes and diabetes Steen Andersen, CEO of ProBiotix commented: " We are pleased with the performance of the business in the first half of the financial year, and the progress we are making. The active customer base has grown by more than 15% during this period, which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products. We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering, expanding sales to include third party distribution and a broadened product positioning to offer LP LDL ® beyond cholesterol health."   For further information, please contact:   ProBiotix Health plc https://probiotixhealth-ir.com/   [email protected] Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations   AlbR Capital Limited Aquis Corporate Adviser and Broker Tel: 020 7469 0930   David Coffman Dan Harris   This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.   Notes to Editors: ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals. The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.   Chief Executive Officer's overview The momentum in the business has continued in the first half of 2026, with record revenue growth and a pleasing increase in our gross margin. Moreover, our stated strategy to increase market awareness and boost market penetration, has led to a significant expansion of the customer base. The Company has continued to expand its global footprint, with the APAC region again proving a particularly strong market. Our partnership with Kemin continues to develop, leading to increasing demand in China. Revenue for the first six months of 2026 reached a record £2.06m, a 53% increase compared with the same period in 2025. As a result of this increased sales traction, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of £151,000 (2025: £112,000 loss). The Board and Management are pleased with the performance achieved in the first half of the year, as it provides further evidence of the success of our strategy. Strategic Outlook As a life sciences company with a strategic focus on probiotics and the human microbiome, there remains a significant market opportunity to continue our expansion. ProBiotix operates in the dietary supplement prevention segment, a market which is being driven by the consumer trend of healthy ageing, cardiometabolic health and probiotics. The strategy continues to target partnerships with scientifically driven dietary supplement suppliers, consumer health and Over the Counter (OTC) companies globally. We continue to provide private label as well as turnkey probiotic dietary supplements to target preventative cardiometabolic health and healthy ageing. The patented LP LDL ® continues to be our flagship probiotic strain, developed specifically to support cardiometabolic health. Results The Group has delivered a solid trading result during the period, with revenue increasing 53% to £2.06m (2025: £1.34m). Gross profit rose to £1.245m (2025: £748,000), which equated to an increased gross margin of 60.4% (2025: 55%). Importantly, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of £151,000 (2025: £112,000 loss). This improvement has been achieved by increased sales volumes, as well as continued operational efficiencies. The Group ended the period with a cash and cash equivalents of £1.244m, compared to £1.3m at the prior period end. The movement in the bank balance arises from a higher net trade debtor position relative to trade creditors at the current period end compared with the prior period . This is sufficient to deliver our expansion ambitions and leaves the Group fully funded as a result. Outlook The active customer base has grown by more than 15% during this period which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products. We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering expanding sales to include third party distribution, and a broadened product positioning to offer LP LDL ® beyond cholesterol health. The Board and wider management team remain fully committed to delivering the growth strategy we have articulated. We would like to thank all our shareholders and wider stakeholders for their support, and view the future with confidence.   Consolidated Statement of Comprehensive Income For the 6 months to 30 June 2026                               6 months to 30 June 2026 Unaudited 6 months to 30 June 2025 Unaudited Year ended 31 December 2025 Audited Continuing operations     £'000 £'000 £'000           Revenue 3 2,059 1,344 2,732           Cost of sales (814) (596) (1,250)   ─────── ─────── ─────── Gross Profit   1,245 748 1,482     Share based payments   (46) (16) (753) Depreciation and amortisation   (26) (25) (54) Other administrative costs   (1,094) (860) (1,910)       ─────── ─────── ─────── Total administrative expenses   (1,166) (901) (2,717)     ─────── ─────── ─────── Operating profit/(loss)   79 (153) (1,235)       Finance income / (costs)   - - -   ─────── ─────── ─────── Profit/(Loss) before Income tax   79 (153) (1,235)     Income tax   7 3 2   ─────── ─────── ─────── Profit/(Loss) for the period   86 (150) (1,233)       Other Comprehensive Income   - - -     ─────── ─────── ─────── Total comprehensive income for the period   86     (150)   (1,233)   ═══════ ═══════ ═══════     Total comprehensive income attributable to the owners of the Group   86 (150)   (1,233)     ═══════ ═══════ ═══════   86 (150) (1,233) Earnings/(loss)  per share     Basic & Diluted - pence 4 0.05p (0.09)p (0.78)p   ═══════ ═══════ ═══════   Consolidated Statement of Financial Position As at 30 June 2026   Notes As at 30 June  2026 Unaudited As at 30 June  2025 Unaudited As at 31 December  2025 Audited ASSETS   £'000 £'000 £'000 Non-current assets   Intangibles   161 211 186 Property plant and equipment   6 7 5   ─────── ─────── ───────     167 218 191     ─────── ─────── ─────── CURRENT ASSETS     Inventories   - 17 - Trade and other receivables   560 846 351 Cash and cash equivalents   1,244 1,299 1,266   ─────── ─────── ───────     1,804 2,162 1,617   ─────── ─────── ─────── TOTAL ASSETS   1,971 2,380 1,808   ═══════ ═══════ ═══════ EQUITY     Shareholders' Equity     Called up share capital 5 79 79 79 Group reorganisation reserve   (945) (945) (945) Share premium   4,534 4,534 4,534 Share based payment reserve   840 57 794 Retained Earnings   (2,933) (1,936) (3,019)       ─────── ─────── ─────── Total Equity   1,575 1,789 1,443     ─────── ─────── ─────── LIABILITIES     Current liabilities     Trade and other payables   356 538 318   ─────── ─────── ───────   356 538 318   ─────── ─────── ─────── Non - current liabilities     Deferred tax liability   40 53 47   ─────── ─────── ───────   40 53 47   ─────── ─────── ─────── TOTAL LIABILITIES   396 591 365     ─────── ─────── ───────       TOTAL EQUITY AND LIABILITIES   1,971 2,380 1,808         ═══════ ═══════ ═══════ Consolidated Statement of Changes in Equity For six months to 30 June 2026   Called up Share Capital Share premium Group Reorganisation reserve Share-based Payment reserve Retained Earnings Total Equity £'000 £'000 £'000 £'000 £'000 £'000 ────── ─────── ─────── ─────── ────── ─────── Balance at 31 December 2024 79 4,534 (945) 41 (1,786) 1,923 Loss for the period - - - - (150) (150) Share based payments - - - 16 - 16 ────── ─────── ─────── ─────── ────── ─────── Balance at 30 June 2025 79 4,534 (945) 57 (1,936) 1,789 Loss for the period - - - - (1,083) (1,083) Share based payments - - - 737 - 737 ────── ─────── ─────── ─────── ────── ─────── Balance at 31  December 2025 79 4,534 (945) 794 (3,019) 1,443 Profit for the period - - - - 86 86 Share based payments - - - 46 - 46 ────── ─────── ─────── ─────── ────── ─────── Balance at 30 June 2026 79 4,534 (945) 840 (2,933) 1,575   ────── ─────── ─────── ─────── ────── ───────   Consolidated Statement of Cash Flows For the six months to 30 June 2026       Notes 6 months to 30 June 2026 Unaudited Period to 30 June 2025 Unaudited Year ended 31 December 2025 Audited   £'000 £'000 £'000 Reconciliation of loss before income tax to cash outflow from operations   Operating profit/(loss)   79 (153) (1,235) Decrease/ (Increase) in inventories   - 14 31 (Increase)/decrease in trade and other receivables   (208) (589) (94) (Decrease)/increase in trade and other payables   38 343 123 Share based payments   46 16 753 Depreciation and amortisation   26 25 54 Net Fx Difference   (3) -   ────── ────── ────── Net cash outflow from operations   (19) (347) (368)     Tax received   - - -   ────── ────── ────── Net cash (outflow)/inflow from operating activities   (19) (347) (368)   Cash flows from investing activities     Purchase of intangible assets   (3) - (12)   ────── ────── ────── Net cash (outflow)/inflow from investing activities   (3) - (12)   ────── ────── ────── Cash flows from financing activities   Share issue net of costs   - - -   ────── ────── ────── Net cash inflow from financing activities   - - -   ────── ────── ──────   Increase/(decrease) in cash and equivalents   (22) (347) (380)     Cash and cash equivalents at beginning of period   1,266 1,646 1,646   ────── ────── ────── Cash and cash equivalents at end of period   1,244 1,299 1,266   ══════ ══════ ══════ Notes to the results   For the six months to 30 June 2026   1.    General Information         ProBiotix Health plc is a c om p a n y i n c o r p o rat e d a n d d om i c il e d in England and Wales. T h e Com p a n y ' s o ffic e s are in Wakefield. T h e C om p a n y is l i st e d o n t h e Aquis Growth M ar ke t (tic ke r: PBX).   The financial information set out in this report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006.  The Group's statutory financial statements for the period ended 31 December 2025 were prepared under UK - adopted International Financial Reporting Standards ("IFRS").   Copies of the annual statutory accounts and the Half Yearly report can be found on the Company's website https://probiotixhealth-ir.com/financials/latest-results   2.    Basis of preparation and significant accounting policies   This report has been prepared using the historical cost convention, on a going concern basis and in accordance with UK - adopted International Financial Reporting Standards ("IFRS"). The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies and making any estimates. Changes in assumptions may have a significant impact on the financial statements in the period the assumptions changed. The Board of Directors believe that the underlying assumptions are appropriate and that the financial statements are fairly presented. The Board of Directors believes that there are no areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, and therefore, these financial statements have limited disclosures.   3.    Segmental Reporting   In the opinion of the directors, the Group has one class of business, in four geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly interconnected markets, all costs assets and liabilities are derived from locations in the UK and Denmark.   Revenue analysed by geographical market   6 months 30 June   2026 6 months 30 June   2025 Year to 31 December 2025   £'000 £'000 £'000 UK - 34 61 US 1,048 760 1,810 China 276 51 - ROW 735 499 861   ────── ────── ──────   2,059 1,344 2,732   ══════ ══════ ══════     During the reporting period one customer represented £1.014m, 49.2% (2025: £689k, 51.2%) of Group revenues.   4.    Earnings per Share           Basic earnings per share is calculated by dividing the earnings attributable shareholders by the weighted average number of ordinary shares outstanding during the period.           Reconciliations are set out below:     6 Months to 30 June 2026 Unaudited 6 Months to 30 June 2025 Unaudited Year to 31 December 2025 Audited   £ £ £ Basic  & Diluted Earnings attributable to ordinary shareholders 86,000 (150,000) (1,233,000) Weighted average number of shares 158,166,666 158,166,666 158,166,666 Earnings /(Loss) per-share - pence 0.05p (0.09)p (0.78)p ═════ ═════ ═════         As at 30 June 2026 there were 14,750,000 (2025: 14,750,000) outstanding share options.  These are non-dilutive due to the strike price being above the share price at the period end.       5.   Share Capital         Issued share capital comprises:     Shares in issue     Opening balance 1 January 2025 and 30 June 2025 158,166,666 ────── Closing balance at 31 December 2025 and 30 June 2026 158,166,666 ══════     Share capital   £'000 Opening balance 1 January 2025 and 30 June 2025 79 ────── Closing balance at 31 December 2025 and 30 June 2026 79 ══════   6.   Post balance sheet events   There are no post balance sheet events.    

View stock analysis, news, and events for Probiotix Health Plc